HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics.
No abstract available
References:
Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023;30(5):4382-4401.
Yee AJ, Raje NS. Panobinostat and multiple myeloma in 2018. Oncologist. 2018;23(5):516-517.
Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). 2019;11(4):475.
Vogl DT, Raje N, Jagannath S, et al. . Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017;23(13):3307-3315.
Lernoux M, Schnekenburger M, Dicato M, Diederich M. Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochem Pharmacol. 2021;188:114526.